363 related articles for article (PubMed ID: 15279663)
1. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.
Yoon SY; Tefferi A; Li CY
Haematologica; 2001 Jan; 86(1):52-7. PubMed ID: 11146571
[TBL] [Abstract][Full Text] [Related]
3. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
4. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
6. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
7. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.
Yoon SY; Li CY; Lloyd RV; Tefferi A
Int J Hematol; 2000 Oct; 72(3):337-42. PubMed ID: 11185990
[TBL] [Abstract][Full Text] [Related]
9. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
12. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
[TBL] [Abstract][Full Text] [Related]
15. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
[TBL] [Abstract][Full Text] [Related]
18. Circulating thrombopoietin in clonal versus reactive thrombocytosis.
Karakuş S; Ozcebe OI; Haznedaroğlu IC; Göker H; Ozatli D; Koşar A; BüyükaşIk Y; Ertuğrul D; SayInalp N; KirazlI S; Dündar SV
Hematology; 2002 Feb; 7(1):9-12. PubMed ID: 12171772
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
Buhr T; Georgii A; Choritz H
Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
